Characterization of cancer-induced bone pain: an exploratory study

PurposeCancer-induced bone pain (CIBP) is the commonest cause of pain in patients with cancer. Its association with increased morbidity combined with limitations of currently available therapies makes it a clinical challenge. Clinical characterization of this complex pain syndrome is essential in underpinning clinical management and informing future research. The aim of this exploratory study was to characterise CIBP using self-rating scales.Patients and methodsA cross-sectional survey of patients with CIBP was carried out in a regional oncology centre. Patients described their pain over the preceding 24 h using the McGill Pain Questionnaire, Brief Pain Inventory (BPI), and a breakthrough pain questionnaire. Multiple linear regression analyses were conducted.ResultsFifty-five patients were recruited. Annoying, gnawing, aching, and nagging were the most commonly used words to describe CIBP. From the BPI, median average pain was 4/10 and worst pain was 7/10 on a 0–10 Numerical Rating Scale. The worst pain score correlated more strongly with BPI interference score (p = 0.001). Forty-one patients had breakthrough pain. Patients with breakthrough pain had higher total BPI interference scores than those with no breakthrough pain; median (IQR); 35.0 (2.5–44.7) vs. 18.5 (5.5–26.7), p < 0.01. Of the patients, 20/41 (48%) had breakthrough pain of rapid onset (less than 5 min) and short duration (less than 15 min).ConclusionIn CIBP, worst pain most accurately reflects the characteristics of pain flares and functional impairment. Breakthrough pain is often unpredictable, sudden onset and short duration. Further characterization studies of CIBP in the broader cancer population are needed

[1]  R. Melzack.  The McGill Pain Questionnaire: Major properties and scoring methods , 1975, PAIN.

[2]  S. Mercadante.  Malignant bone pain: pathophysiology and treatment , 1996, Pain.

[3]  E. Zecca,et al.  Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey , 2004, Palliative medicine.

[4]  H. Thaler,et al.  Pain in ambulatory patients with lung or colon cancer. Prevalence, characteristics, and effect , 1992, Cancer.

[5]  J. Lau,et al.  Nonsteroidal anti-inflammatory drugs, alone or combined with opioids, for cancer pain: a systematic review. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Mercadante,et al.  Predictive factors in advanced cancer pain treated only by analgesics , 1992, Pain.

[7]  Ronald Melzack,et al.  Handbook of pain assessment , 1992 .

[8]  Nicholas A. Christakis,et al.  Oxford Textbook of Palliative Medicine , 2011 .

[9]  R. Coleman.  Skeletal complications of malignancy , 1997, Cancer.

[10]  A. Duncan.  The use of fentanyl and alfentanil sprays for episodic pain , 2002, Palliative Medicine.

[11]  R. Portenoy,et al.  Breakthrough pain: definition, prevalence and characteristics , 1990, Pain.

[12]  E. Bruera,et al.  A prospective multicenter assessment of the Edmonton staging system for cancer pain. , 1995, Journal of pain and symptom management.

[13]  E. Chow,et al.  Worst, average or current pain in the Brief Pain Inventory: which should be used to calculate the response to palliative radiotherapy in patients with bone metastases? , 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).

[14]  C. Cleeland,et al.  Pain assessment: global use of the Brief Pain Inventory. , 1994, Annals of the Academy of Medicine, Singapore.

[15]  S. Kaasa,et al.  Episodic (breakthrough) pain , 2002, Cancer.

[16]  P. Mantyh,et al.  Efficacy of systemic morphine suggests a fundamental difference in the mechanisms that generate bone cancer vs. inflammatory pain , 2002, Pain.

[17]  M. Simmonds,et al.  Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  C. Cleeland,et al.  Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases , 1983, Pain.

[19]  N. Slatkin,et al.  Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. , 2007, The journal of supportive oncology.

[20]  R. Moore,et al.  Radiotherapy for the palliation of painful bone metastases. , 2000, The Cochrane database of systematic reviews.

[21]  M. Nabal,et al.  Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. , 2002, Journal of pain and symptom management.

[22]  S. Johnston,et al.  Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer , 2003, BMJ : British Medical Journal.

[23]  P. Fine,et al.  Characterization of breakthrough pain by hospice patients and their caregivers. , 1998, Journal of pain and symptom management.

[24]  Ronald Melzack,et al.  The McGill Pain Questionnaire: Appraisal and current status. , 2001 .

[25]  Jesse A. Berlin,et al.  Defining the clinically important difference in pain outcome measures , 2000, PAIN.

[26]  R. Coleman,et al.  The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia , 2003, Palliative medicine.

[27]  S. Mercadante,et al.  Breakthrough pain in cancer patients: pathophysiology and treatment. , 1998, Cancer treatment reviews.

[28]  F. Mosteller,et al.  Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: a meta-analysis. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  C. Cleeland,et al.  Development of a Cancer Pain Assessment Tool in Korea: A Validation Study of a Korean Version of the Brief Pain Inventory , 2004, Oncology.

[30]  Paul Jacobsen,et al.  Breakthrough pain: characteristics and impact in patients with cancer pain , 1999, Pain.

[31]  R. Portenoy,et al.  A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. , 2002, The journal of pain : official journal of the American Pain Society.

[32]  A. Banning,et al.  Pain causes in 200 patients referred to a multidisciplinary cancer pain clinic , 1991, Pain.

[33]  G. Hanks,et al.  Opioid Analgesic Therapy , 2003 .

[34]  M. Bennett,et al.  The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs , 2001, Pain.

[35]  W. Sze,et al.  Meta-analysis of Palliative Radiotherapy Trials for Bone Metastases , 2007 .

[36]  L. Tremmel,et al.  A Randomized, Placebo-controlled Study of Fentanyl Buccal Tablet for Breakthrough Pain in Opioid-treated Patients With Cancer , 2006, The Clinical journal of pain.

[37]  B. Kasimis,et al.  Cancer breakthrough pain characteristics and responses to treatment at a VA medical center , 2003, Pain.